Literature DB >> 21782780

Annexin 1 released by necrotic human glioblastoma cells stimulates tumor cell growth through the formyl peptide receptor 1.

Yan Yang1, Ying Liu, Xiaohong Yao, Yifang Ping, Tao Jiang, Qin Liu, Senlin Xu, Jian Huang, Haiwei Mou, Wanghua Gong, Keqiang Chen, Xiuwu Bian, Ji Ming Wang, Ji Ming Wang.   

Abstract

Highly malignant human gliomas overexpress the G-protein-coupled chemoattractant receptor formyl peptide receptor (FPR1), which promotes tumor progression when activated. Our previous studies demonstrated that necrotic glioblastoma cells release chemotactic agonist(s) that activate FPR1 on viable tumor cells. In the present study, we identified an FPR1 agonist released by necrotic human glioblastoma cells. Necrotic tumor cell supernatant (NecSup) contained Annexin 1 (Anx A1), a chemotatic polypeptide agonist for FPR1. Immunoabsorption of Anx A1 with a specific antibody markedly reduced the chemotactic activity of NecSup for tumor cells and diminished its capacity to promote tumor cell growth, invasion, and colony formation on soft agar. In addition, Anx A1 was present in tumor xenografts formed by human glioblastoma cells in nude mice. Anx A1 knockdown significantly reduced the tumorigenicity of glioblastoma cells in nude mice, but FPR1/Anx A1 double knockdown diminished tumor growth even further. The clinical relevance of Anx A1 in gliomas was supported by the observation that Anx A1 was more highly expressed in poorly differentiated human primary gliomas compared with lower grade tumors. Our study implicates Anx A1 as a major component in necrotic tumor cell-derived stimulants of the growth of glioblastoma via the activation of FPR1.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21782780      PMCID: PMC3157278          DOI: 10.1016/j.ajpath.2011.05.059

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

Review 1.  Formyl-peptide receptors revisited.

Authors:  Yingying Le; Philip M Murphy; Ji Ming Wang
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

Review 2.  The microenvironment of the tumour-host interface.

Authors:  L A Liotta; E C Kohn
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

3.  Inhibition of neutrophil and monocyte recruitment by endogenous and exogenous lipocortin 1.

Authors:  S J Getting; R J Flower; M Perretti
Journal:  Br J Pharmacol       Date:  1997-03       Impact factor: 8.739

4.  Silencing the formylpeptide receptor FPR by short-interfering RNA.

Authors:  Yingying Le; Pablo Iribarren; Ye Zhou; Wanghua Gong; Jinyue Hu; Xia Zhang; Ji Ming Wang
Journal:  Mol Pharmacol       Date:  2004-07-16       Impact factor: 4.436

5.  Formylpeptide receptor FPR and the rapid growth of malignant human gliomas.

Authors:  Ye Zhou; Xiuwu Bian; Yingying Le; Wanghua Gong; Jinyue Hu; Xia Zhang; Lihua Wang; Pablo Iribarren; Rosalba Salcedo; O M Zack Howard; William Farrar; Ji Ming Wang
Journal:  J Natl Cancer Inst       Date:  2005-06-01       Impact factor: 13.506

6.  Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics.

Authors:  M Perretti; S J Getting; E Solito; P M Murphy; J L Gao
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

7.  Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR.

Authors:  Marie-Josèphe Rabiet; Emilie Huet; François Boulay
Journal:  Eur J Immunol       Date:  2005-08       Impact factor: 5.532

Review 8.  Lipocortin-1: cellular mechanisms and clinical relevance.

Authors:  R J Flower; N J Rothwell
Journal:  Trends Pharmacol Sci       Date:  1994-03       Impact factor: 14.819

9.  Overexpression of annexin 1 in pancreatic cancer and its clinical significance.

Authors:  Xiao-Feng Bai; Xiao-Guang Ni; Ping Zhao; Shang-Mei Liu; Hui-Xin Wang; Bing Guo; Lan-Ping Zhou; Fang Liu; Jin-Sheng Zhang; Kun Wang; Yong-Qiang Xie; Yong-Fu Shao; Xiao-Hang Zhao
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

10.  Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor.

Authors:  Ronghua Sun; Pablo Iribarren; Ning Zhang; Ye Zhou; Wanghua Gong; Edward H Cho; Stephen Lockett; Oleg Chertov; Filip Bednar; Thomas J Rogers; Joost J Oppenheim; Ji Ming Wang
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

View more
  30 in total

Review 1.  Chemoattractant receptors as pharmacological targets for elimination of glioma stem-like cells.

Authors:  Xiao-hong Yao; Ying Liu; Keqiang Chen; Wanghua Gong; Ming-yong Liu; Xiu-wu Bian; Ji Ming Wang
Journal:  Int Immunopharmacol       Date:  2011-09-17       Impact factor: 4.932

Review 2.  G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues.

Authors:  A E Cherry; N Stella
Journal:  Neuroscience       Date:  2014-08-24       Impact factor: 3.590

3.  Formylpeptide receptor 1 mediates the tumorigenicity of human hepatocellular carcinoma cells.

Authors:  Liang Zhang; Huanyu Wang; Tianshu Yang; Zhifeng Su; Dan Fang; Yafeng Wang; Jiazhu Fang; Xinwei Hou; Yingying Le; Keqiang Chen; Ji Ming Wang; Shao Bo Su; Qing Lin; Qi Zhou
Journal:  Oncoimmunology       Date:  2015-08-24       Impact factor: 8.110

4.  High-mobility group box 1 released by autophagic cancer-associated fibroblasts maintains the stemness of luminal breast cancer cells.

Authors:  Xi-Long Zhao; Yong Lin; Jun Jiang; Zhuo Tang; Shuai Yang; Lu Lu; Yan Liang; Xue Liu; Jiao Tan; Xu-Gang Hu; Qin Niu; Wen-Juan Fu; Ze-Xuan Yan; De-Yu Guo; Yi-Fang Ping; Ji Ming Wang; Xia Zhang; Hsiang-Fu Kung; Xiu-Wu Bian; Xiao-Hong Yao
Journal:  J Pathol       Date:  2017-09-21       Impact factor: 7.996

5.  Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways.

Authors:  Nella Prevete; Federica Liotti; Anna Illiano; Angela Amoresano; Piero Pucci; Amato de Paulis; Rosa Marina Melillo
Journal:  Oncoimmunology       Date:  2017-02-21       Impact factor: 8.110

Review 6.  Molecular biology for formyl peptide receptors in human diseases.

Authors:  Yongsheng Li; Duyun Ye
Journal:  J Mol Med (Berl)       Date:  2013-02-13       Impact factor: 4.599

7.  The G-protein coupled chemoattractant receptor FPR2 promotes malignant phenotype of human colon cancer cells.

Authors:  Yi Xiang; Xiaohong Yao; Keqiang Chen; Xiafei Wang; Jiamin Zhou; Wanghua Gong; Teizo Yoshimura; Jiaqiang Huang; Rongquan Wang; Yuzhang Wu; Guochao Shi; Xiuwu Bian; Jiming Wang
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

Review 8.  Regulation of inflammation by members of the formyl-peptide receptor family.

Authors:  Keqiang Chen; Zhiyao Bao; Wanghua Gong; Peng Tang; Teizo Yoshimura; Ji Ming Wang
Journal:  J Autoimmun       Date:  2017-07-06       Impact factor: 7.094

9.  Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics.

Authors:  Maxime S Heroux; Marla A Chesnik; Brian D Halligan; Mona Al-Gizawiy; Jennifer M Connelly; Wade M Mueller; Scott D Rand; Elizabeth J Cochran; Peter S LaViolette; Mark G Malkin; Kathleen M Schmainda; Shama P Mirza
Journal:  Physiol Genomics       Date:  2014-05-06       Impact factor: 3.107

Review 10.  G protein-coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma.

Authors:  Mingyong Liu; Jianhua Zhao; Keqiang Chen; Xiuwu Bian; Chunyan Wang; Ying Shi; Ji Ming Wang
Journal:  Int Immunopharmacol       Date:  2012-08-02       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.